Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06579092 · ClinicalTrials.gov registry record · Phase 2
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 310
- Enrollment target
NCT06579092: Completed Phase 2 study, sponsored by AstraZeneca.
NCT06579092 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 310 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06579092, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 310 participants
- Enrollment target
Study Summary
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity
Primary Outcome
To determine whether AZD5004 is superior to placebo for weight loss
Interventions
- DRUG Placebo
- DRUG AZD5004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2025-11-21 |
| Phase | Phase 2 |
What the finished NCT06579092 record still lists
NCT06579092 is an interventional study that assigns participants to a tested intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06579092 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06579092 about?
NCT06579092 is a clinical study titled "Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity". A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with ob...
What is the current status of trial NCT06579092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2024-10-08. Estimated completion is 2025-11-21.
What interventions are being tested in trial NCT06579092?
The interventions under investigation include: Placebo (DRUG), AZD5004 (DRUG).
Who is sponsoring clinical trial NCT06579092?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06579092's enrollment target sits among peer trials
310 162nd of 2000 higher than 1,838 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI